Description: Klotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.
Home Page: www.klothoneuro.com
13576 Walnut Street
Omaha,
NE
68144
United States
Phone:
833 931 6330
Officers
| Name | Title |
|---|---|
| Mr. Peter J. Moriarty | Chief Operating Officer |
| Dr. Shalom Z. Hirschman M.D. | Medical Advisor & Director |
| Dr. Joseph Sinkule Pharm.D. | Founder, CEO, Chairman of the Board & Secretary |
| Mr. Jeffrey LeBlanc | Chief Financial Officer |
| Dr. Miguel Chillon Rodriguez | Chief Scientific Officer & Consultant |
| Dr. Bradford A. Navia M.D., Ph.D. | Chief Medical Advisor |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 43.3635 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2024-09-17 |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |